天康生物(002100) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3,890,843,979.48, representing a 14.71% increase compared to CNY 3,391,929,405.09 in the same period last year[18]. - The net loss attributable to shareholders of the listed company was CNY -14,282,251.76, a significant improvement of 79.48% from CNY -69,605,796.25 year-on-year[18]. - The net profit for the current period was -17,149,045.31, compared to -108,566,710.19 in the previous period, indicating an improvement[32]. - The total comprehensive income for the current period was -7,300,826.24, compared to -188,142,159.14 in the previous period, showing a significant reduction in losses[33]. - The basic and diluted earnings per share for the current period were both -0.01, compared to -0.05 in the previous period[33]. Cash Flow - The net cash flow from operating activities improved by 35.21%, amounting to CNY -523,750,573.77, compared to CNY -808,347,021.44 in the previous year[21]. - Cash flow from operating activities resulted in a net outflow of -523,750,573.77, an improvement from -808,347,021.44 in the previous period[33]. - Cash flow from investing activities generated a net inflow of 474,080,713.81, compared to a net outflow of -204,891,989.28 in the previous period[34]. - Cash flow from financing activities resulted in a net inflow of 651,284,449.71, compared to a net outflow of -122,578,555.00 in the previous period[34]. - The company reported cash and cash equivalents at the end of the period amounting to 3,802,570,554.95, up from 2,175,960,504.84 in the previous period[34]. Assets and Liabilities - The total assets as of March 31, 2023, were CNY 20,374,771,227.30, reflecting a 5.24% increase from CNY 19,360,994,902.71 at the end of the previous year[18]. - The total liabilities as of Q1 2023 amounted to approximately RMB 10.61 billion, compared to RMB 9.70 billion in the previous year, indicating a year-over-year increase of 9.4%[30]. - Current assets rose to CNY 12,990,493,336.65, up from CNY 12,412,059,821.41, indicating an increase of about 4.65%[41]. - The total current liabilities increased to CNY 7,315,031,840.16 from CNY 6,173,714,914.84, representing a rise of about 18.46%[42]. - Non-current liabilities decreased to CNY 3,290,328,060.73 from CNY 3,522,309,214.78, showing a reduction of about 6.58%[42]. Equity and Investments - The company’s total equity attributable to shareholders was CNY 8,039,387,885.55, a slight increase of 1.13% from CNY 7,949,867,246.11 at the end of the previous year[18]. - The total equity attributable to minority shareholders was approximately RMB 1.73 billion, compared to RMB 1.72 billion in the previous year, indicating stability in minority interests[30]. - The company's long-term equity investments decreased to CNY 21,357,276.88 from CNY 105,445,142.28, a decline of approximately 79.73%[42]. Research and Development - The company increased its research and development expenditure to CNY 12,982,627.27, a rise of 68.48% from CNY 7,705,622.64 in the previous year[7]. - Research and development expenses for Q1 2023 were approximately RMB 40.16 million, slightly up from RMB 38.13 million in Q1 2022, indicating a focus on innovation[30]. Management and Operational Efficiency - The company reported a decrease in management expenses by 28.63%, amounting to CNY 104,830,863.20 compared to CNY 146,883,773.68 in the previous year[7]. - The company reported a decrease in management expenses to approximately RMB 104.83 million from RMB 146.88 million, showing improved cost management[30]. - The company recorded operating profit of 10,831,007.05, a significant recovery from -87,755,749.48 in the previous period[32]. Strategic Acquisitions - The company completed the acquisition of 100% equity in Guanjie Company, which is now a wholly-owned subsidiary, enhancing its market position[26]. - The company plans to acquire a 100% stake in Guanjie Biotechnology Co., Ltd. for a total price of 655,100,000.00, enhancing its market position[39]. - The company has engaged with 17 counterparties to sign conditional equity transfer agreements, indicating ongoing strategic expansion efforts[26]. Revenue and Costs - Total operating revenue for Q1 2023 was approximately RMB 3.89 billion, an increase of 14.7% compared to RMB 3.39 billion in Q1 2022[30]. - Total operating costs for Q1 2023 were approximately RMB 3.87 billion, up from RMB 3.50 billion in Q1 2022, reflecting a year-over-year increase of 10.6%[30]. - The company reported a total revenue from sales of goods and services amounting to 3,574,616,196.13, compared to 3,148,399,562.50 in the previous period, reflecting growth[33].